Education
About Us
Working with TipRanks
Follow Us
InfuSystem Holdings, Inc. (INFU)
XASE:INFU
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and financial momentum: revenue and record adjusted EBITDA growth, stronger margins, robust cash generation, reduced net debt and substantial liquidity. Management acknowledged short-term headwinds including a deliberate revenue reduction from a restructured GE contract, temporary ERP implementation costs and some reimbursement/regulatory uncertainty (ChemoMouthpiece). However, management framed the contract restructuring and system upgrades as strategic moves that will improve profitability and scalability, and highlighted significant product-led growth (notably wound care/PCDs) and expected ERP-related cost savings (~$2 million annually). On balance, the positive performance metrics, liquidity and clear path to margin/cost improvements outweigh the near-term challenges and uncertainties.Company Guidance
Top-line Growth
Net revenue for Q4 2025 was $36.2 million, a $2.4 million or 7% increase year-over-year; management reported full-year top-line growth of 7%.
Record Adjusted EBITDA and Margin Expansion
Q4 adjusted EBITDA was $8.8 million, up just over $1.3 million or 17% versus prior-year Q4, representing a record quarterly adjusted EBITDA margin of 24.3% (vs. 22.2% prior year). Full-year adjusted EBITDA was $31.5 million, up $6.2 million or 24.3% with margin up to 21.9% from 18.8% in 2024.
Strong Operating Cash Flow and Cash Generation
Generated operating cash flow of over $24.4 million for 2025 (nearly $4 million or 19% higher than 2024); management also cited strong operating cash flow of $7.1 million in the quarter.
Balance Sheet Strength and Liquidity
Net debt decreased by $6.9 million (a ~30% year-over-year decline per management); available liquidity totaled nearly $58 million as of December 31, 2025 and net debt/adjusted EBITDA was a modest 0.52x.
Wound Care Surge and New Product Ramp
Wound care treatment volume revenue grew by nearly $900,000 in Q4, representing over 160% growth year-over-year, driven largely by pneumatic compression device (PCD) launches and the migration to the new revenue cycle application.
Device Solutions Growth
Device Solutions net revenue increased $1.3 million or 9.7% in Q4, driven by $1 million higher medical equipment sales (including rental buyouts) and ~ $600,000 higher biomedical services revenue from a more diverse smaller-customer base.
Operational Efficiency and Gross Margin Improvement
Gross profit for Q4 was $20.4 million, up $2.2 million or 12%; gross margin improved to just over 56%, up 2.6 percentage points YoY, attributed to labor efficiency, pricing, improved revenue mix, lower procurement and maintenance/disposable costs.
ERP & Revenue Cycle Migrations Near Completion with Expected Cost Savings
Completed migration of Wound Care to the new revenue cycle app and ERP go-live expected in Q1 2026. Management expects net annual savings of about $2 million once ERP implementation costs decline and longer-term productivity gains to follow.
Capital Allocation — Share Repurchase and Lower CapEx
Returned capital via share repurchases (137,000 shares in Q4 and 1.3 million for the full year; ~$9.9 million spent on buybacks during 2025). Net capital expenditures fell to $6.8 million in 2025 from $13.2 million in 2024, with management expecting continued lower capital intensity.
Accreditations and Product Pipeline Expansion
Obtained new accreditations for additional DME products (examples cited: Defender Boot and HidraWear ostomy product) and reported ongoing efforts to add new products and customers (including plans to migrate Oncology into the revenue cycle system).
INFU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INFU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $7.58 | $8.60 | +13.46% |
Nov 04, 2025 | $10.40 | $9.46 | -9.04% |
Aug 05, 2025 | $5.85 | $6.07 | +3.76% |
May 08, 2025 | $4.75 | $5.47 | +15.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does InfuSystem Holdings, Inc. (INFU) report earnings?
InfuSystem Holdings, Inc. (INFU) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is InfuSystem Holdings, Inc. (INFU) earnings time?
InfuSystem Holdings, Inc. (INFU) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INFU EPS forecast?
INFU EPS forecast for the fiscal quarter 2026 (Q1) is 0.03.